Design Therapeutics Inc. (DSGN)
NASDAQ: DSGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
DSGN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $577.61M
- EPS (TTM)
- -$1.20
- Dividend yield
- None
- 52-week range
- 8.21 – 17.25
- Day range
- 8.97 – 9.57
- Volume / Avg
- 281.93K / 554.69K
- Beta
- —
- Shares outstanding
- 64.04M
52-week range
DSGN stock today
Design Therapeutics (DSGN) closed at $9.02 on Nov 20, down 3.22% (-$0.30), versus the S&P 500's 3.70% decline. At this level, DSGN sits near the bottom of its 52-week range of $8.21 to $17.25: 47.7% below the high, set on Apr 29, 2026 and 9.9% above the low. DSGN is down 3.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 8.0%.
Design Therapeutics has posted a net loss over the last twelve months (EPS of -$1.20), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Design Therapeutics
Company profileDesign Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Pratik Shah Ph.D.
- Headquarters
- Carlsbad, CA
- Employees
- 60
- IPO year
- 2021
- Website
- designtx.com
Financial highlights
Full financialsIn fiscal 2025, Design Therapeutics generated $0 in revenue, up 0.0% from fiscal 2024. Design Therapeutics reported a net loss of $69.8 million, compared with a loss of $49.6 million a year earlier. Diluted earnings per share came in at -$1.22.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-69.79M | $-49.59M | $-66.86M | $-63.31M | $-35.53M |
| EPS (diluted) | $-1.22 | $-0.88 | $-1.19 | $-1.14 | $-0.77 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$21.57+139.14%
- Strong buy 2
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.32 vs $-0.38
- Surprise
- +15.79%
DSGN news
All DSGN newsDesign Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IMMXImmix Biopharma Inc. | 6.96 | -1.14% | $583.33M | vs DSGN |
| ANNXAnnexon Inc. | 3.10 | -9.09% | $591.37M | vs DSGN |
| GERNGeron Corporation | 0.8707 | -4.63% | $560.94M | vs DSGN |
| BCAXBicara Therapeutics Inc. | 8.44 | -7.46% | $560.31M | vs DSGN |
| ANLAdlai Nortye Group Ltd. ADR | 8.55 | -5.63% | $550.60M | vs DSGN |
| ACRSAclaris Therapeutics Inc. | 3.44 | -1.71% | $545.63M | vs DSGN |
| AVBPArriVent BioPharma Inc. | 10.52 | -6.57% | $544.13M | vs DSGN |
| CBIOCrescent Biopharma Inc. | 13.00 | +0.70% | $543.21M | vs DSGN |
Indexes, lists and sector
Design Therapeutics stock FAQ
What is Design Therapeutics's stock price today?
DSGN last traded at $9.02 as of Nov 20, 4:00 PM EST, down 3.22% on the day. Prices are delayed at least 15 minutes.
Who is Design Therapeutics's CEO?
Mr. Pratik Shah Ph.D. is the chief executive officer of Design Therapeutics Inc., which has about 60 employees.
What is the DSGN 52-week high?
The 52-week high for DSGN is $17.25 and the 52-week low is $8.21. The stock is currently 47.7% below its high.